Anja Kolarič (Avtor), Marko Anderluh (Avtor), Nikola Minovski (Avtor)

Povzetek

The emergence of bacterial resistance against life-saving medicines has forced the scientific community and pharmaceutical industry to take actions in the quest for novel antibacterials. These should not only overcome the existing bacterial resistance, but also provide at least interim effective protection against emerging bacterial infections. Research into DNA gyrase and topoisomerase IV inhibitors has become a particular focus, with the description of a new class of bacterial topoisomerase type II inhibitors known as "novel bacterial topoisomerase inhibitors" NBTIs. Elucidation of the key structural modifications incorporated into these inhibitors and the impact these can have on their general physicochemical properties are detailed in this review. This defines novel bacterial topoisomerase inhibitors with promising antibacterial activities and potencies, which thus represent one potential example of the future "drugs for bad bugs", as identified by the World Health Organization.

Ključne besede

zaviralci DNA giraze;topoizomeraza tip II;DNA gyrase inhibitors;antibacterials;novel bacterial topoisomerase inhibitors;intercalators;

Podatki

Jezik: Angleški jezik
Leto izida:
Tipologija: 1.01 - Izvirni znanstveni članek
Organizacija: UL FFA - Fakulteta za farmacijo
UDK: 615.015.8
COBISS: 4880241 Povezava se bo odprla v novem oknu
ISSN: 0022-2623
Št. ogledov: 12
Št. prenosov: 6
Ocena: 0 (0 glasov)
Metapodatki: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Ostali podatki

Sekundarni jezik: Slovenski jezik
Sekundarne ključne besede: Bakterijska rezistenca;
Vrsta dela (COBISS): Članek v reviji
Strani: str. 5664-5674
Letnik: ǂVol. ǂ63
Zvezek: ǂiss. ǂ11
Čas izdaje: 2020
DOI: 10.1021/acs.jmedchem.9b01738
ID: 16706512